Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.

The present invention relates to novel 5HT receptor modulators, such as compounds of the general Formula (I) and general Formula (II):

##STR00001##

or a pharmaceutically acceptable salt thereof. Methods of using the compounds include, for example, modulation of 5-hydroxytryptamine (5-HT) receptor subtypes, including 5-hydroxytryptamine 2A receptor and/or 5-hydroxytryptamine 2C receptor, and treatment of a condition or disease where the treatment is associated with the modulation of 5-hydroxytryptamine 2A receptor and/or 5-hydroxytryptamine 2C receptor.

The present invention relates to novel 5HT receptor modulators, such as compounds of the general Formula (I) and general Formula (II):

##STR00001##

or a pharmaceutically acceptable salt thereof. Methods of using the compounds include, for example, modulation of 5-hydroxytryptamine (5-HT) receptor subtypes, including 5-hydroxytryptamine 2A receptor and/or 5-hydroxytryptamine 2C receptor, and treatment of a condition or disease where the treatment is associated with the modulation of 5-hydroxytryptamine 2A receptor and/or 5-hydroxytryptamine 2C receptor.

Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.

Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.